Drug Trial Radar · NCT03063086
Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.
Last checked: Nov 19, 2026Latest source record: Oct 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Jan 21, 2017
Primary completion
Aug 2, 2018
Study completion Aug 2, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess peak FEV1 of two doses of QVM149 compared to a fixed-dose combination of salmeterol/fluticasone (50/500μg b.i.d.) and to characterize the respective 24 hour bronchodilator effect profiles in patients with asthma. Data from this study will complement lung function data obtained in the pivotal QVM149 phase 3 program by assessing the bronchodilatory effect of QVM149 at multiple time-points over an entire dosing interval of 24 hours.
Conditions
- Asthma
Interventions
QVM149 150/50/80 μg o.d.Drug
A
QVM149 150/50/160 μg o.d.Drug
B
salmeterol/fluticasone FDC 50/500 μg b.i.d.Drug
C
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment PeriodTime frame: 3 weeks
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Changchun, Jilin, China
Novartis Investigative Site
Tianjin, Tianjin Municipality, China
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Großhansdorf, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Wiesbaden, Germany
Novartis Investigative Site
Groningen, GZ, Netherlands
Novartis Investigative Site
Bucharest, Romania
Novartis Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.